<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amyl nitrite: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amyl nitrite: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amyl nitrite: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11464" href="/d/html/11464.html" rel="external">see "Amyl nitrite: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F135363"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F135350"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9fb09f2-25f6-4f6a-9461-99a4582cdf73">Provocation of latent left ventricular outflow tract gradient in hypertrophic cardiomyopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Provocation of latent left ventricular outflow tract gradient in hypertrophic cardiomyopathy (off-label use):</b>
<b>Nasal inhalation:</b> 3 to 4 deep inhalations from 1 crushed ampul over a 10 to 15 second period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21514501','lexi-content-ref-15901303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21514501','lexi-content-ref-15901303'])">Ref</a></span>). <b>Note:</b> The use of more physiologic testing (eg, Valsalva maneuver, treadmill testing with Doppler echocardiography) may be preferred over amyl nitrite inhalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21514501','lexi-content-ref-14607462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21514501','lexi-content-ref-14607462'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doe drugH1Div" id="F135351"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F135327"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing, hypotension, orthostatic hypotension, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal incontinence, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, cerebral ischemia, dizziness, headache, restlessness</p></div>
<div class="block coi drugH1Div" id="F135340"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Glaucoma; recent head trauma or cerebral hemorrhage; pregnancy.</p></div>
<div class="block war drugH1Div" id="F135324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Amyl nitrite may cause severe hypotension; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients with preexisting diminished oxygen or cardiovascular reserve (eg, anemia, substantial blood loss, cardiac or respiratory compromise) and in patients who may be susceptible to injury from vasodilation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Amyl nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation. Use with caution in patients with preexisting diminished oxygen or cardiovascular reserve (eg, anemia, substantial blood loss, cardiac or respiratory compromise) and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency). Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin, phenazopyridine).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with extreme caution or avoid in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia; considered by some to be a contraindication (Wesley Reagan 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with coronary artery disease and patients with hypotension. Transient episodes of dizziness, weakness, syncope, and cerebral ischemia secondary to postural hypotension may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: Use with caution in patients with increased intracranial pressure; use is contraindicated in patient with recent head trauma or cerebral hemorrhage.</p></div>
<div class="block foc drugH1Div" id="F135335"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid, for inhalation: USP: 85% to 103% (0.3 mL)</p></div>
<div class="block geq drugH1Div" id="F135321"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322991"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Amyl Nitrite Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mL (1): $0.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provided represent a median AWP and/or AAWP price for the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for charging or reimbursement functions. Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F135337"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Inhalation:</b> Administer nasally via inhalation. The patient should be lying down during administration. Crush the ampul in a gauze pad and place in front of patient's mouth. One ampul lasts for ~3 minutes.</p></div>
<div class="block off-label drugH1Div" id="F25724845"><span class="drugH1">Use: Off-Label: Adult</span><p>Provocation of latent left ventricular outflow tract gradient in hypertrophic cardiomyopathy</p></div>
<div class="block mst drugH1Div" id="F56411360"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298751"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F135329"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Amyl Nitrite.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Amyl Nitrite may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13315273"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amyl nitrite significantly decreases systemic BP and blood flow to the placenta. Amyl nitrite may also cause methemoglobin formation resulting in diminished oxygen-carrying capacity; fetal hemoglobin may be more susceptible to excessive nitrite-induced methemoglobinemia (Valenzuela 1986).</p>
<p style="text-indent:0em;margin-top:2em;">Use in pregnancy is contraindicated for indications in the FDA-approved product labeling.</p></div>
<div class="block brc drugH1Div" id="F20531506"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if amyl nitrite is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering amyl nitrite to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F135333"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor BP and heart rate during therapy.</p></div>
<div class="block pha drugH1Div" id="F2508782"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Relaxes vascular smooth muscle; decreases venous ratios and arterial BP; reduces left ventricular work; decreases myocardial O<sub>2</sub> consumption.</p></div>
<div class="block phk drugH1Div" id="F135339"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 30 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 3 to 15 minutes; Pharmacologic provocation of latent left ventricular outflow tract gradient in hypertrophic cardiomyopathy: ~30 seconds (Wesley Reagan 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Inhalation: Readily absorbed through respiratory tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: In the liver to form inorganic nitrates (less potent).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Amyl nitrite: &lt;1 hour; Methemoglobin: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~33%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58186652"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nitramyl</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nitramyl</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amylnitrit</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nitrito amilo</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amyl nitri</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amyl nitrite afp | Amyl nitrite sankyo</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nitramyl</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nitramyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ATSDR.1">
<a name="ATSDR.1"></a>Agency for Toxic Substances and Disease Registry (ATSDR). Medical Management Guidelines for Hydrogen Cyanide (HCN). <a href="https://www.atsdr.cdc.gov/MHMI/mmg8.pdf" target="_blank">http://www.atsdr.cdc.gov/MHMI/mmg8.pdf</a>.</div>
</li>
<li>
<div class="reference">
                  Amyl nitrite [prescribing information]. Blairstown, NJ: The James Alexander Corporation; December 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4320419">
<a name="4320419"></a>Berlin CM. The treatment of cyanide poisoning in children. <i>Pediatrics.</i> 1970;46(5):793-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/4320419/pubmed" id="4320419" target="_blank">4320419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18820172">
<a name="18820172"></a>Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused Update Incorporated into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2008;118(15):e523-e661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/18820172/pubmed" id="18820172" target="_blank">18820172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28494173">
<a name="28494173"></a>De Capitani EM, Borrasca-Fernandes CF, Branco Pimenta M, et al. Suicide attempt with acetonitrile ingestion in a nursing mother. <i>Clin Toxicol (Phila)</i>. 2017;55(8):929-933. doi:10.1080/15563650.2017.1324977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/28494173/pubmed" id="28494173" target="_blank">28494173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079589">
<a name="17079589"></a>Geller RJ, Barthold C, Saiers JA, et al. Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. <i>Pediatrics.</i> 2006;118(5):2146-2158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/17079589/pubmed" id="17079589" target="_blank">17079589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holstege.1">
<a name="Holstege.1"></a>Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. In: Nelson LS, Howland M, Lewin NA, et al, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. McGraw-Hill Education; 2019: 1684-1693.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holstege.2">
<a name="Holstege.2"></a>Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. <i>Goldfrank's Toxicologic Emergencies</i>. 10th ed. Hoffman RS, Howland MA, Lewin NA, Nelson LS, et al, eds. McGraw-Hill Companies Inc; 2015:1602-1611.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14607462">
<a name="14607462"></a>Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. <i>J Am Coll Cardiol.</i> 2003;42(9):1687-1713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/14607462/pubmed" id="14607462" target="_blank">14607462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21514501">
<a name="21514501"></a>Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients With hypertrophic Cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. <i>J Am Soc Echocardiogr.</i> 2011;24(5):473-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/21514501/pubmed" id="21514501" target="_blank">21514501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20843773">
<a name="20843773"></a>Nichol LM, Mills NL, Starkey IR. Amyl nitrite induced cerebral and coronary vasospasm. <i>QJM. </i>2011;104(1):83-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/20843773/pubmed" id="20843773" target="_blank">20843773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2419158">
<a name="2419158"></a>Valenzuela A, Guerra R, Lazcano L, et al. Differential prooxidative effect of adult and fetal hemoglobin. <i>FEBS Lett.</i> 1986;196(2):353-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/2419158/pubmed" id="2419158" target="_blank">2419158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15901303">
<a name="15901303"></a>Wesley Reagan B, Helmcke F, Kenneth Kerut E. Commonly used respiratory and pharmacologic interventions in the echocardiography laboratory. <i>Echocardiography.</i> 2005;22(5):455-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amyl-nitrite-drug-information/abstract-text/15901303/pubmed" id="15901303" target="_blank">15901303</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8767 Version 178.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
